Indian listed arm of P&G's Gillette, selling razors, blades and other male grooming products.
Indian listed arm of P&G's Gillette, selling razors, blades and other male grooming products.
Sells brands owned by Procter & Gamble, so it pays royalties and technology fees to the parent and buys some goods from group companies, while P&G holds the majority of its shares. Reaches shoppers through distributors to general stores and modern retail chains.
Moat: narrow (brand, IP / patents, distribution). Global Gillette brand and blade-technology patents support premium pricing versus local razors.
Headquarters: Mumbai, India · Founded: 1984 · Employees: 1,098
Size Gillette India (GILLETTE.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $2.53B, the 325th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹7,252 on 18 Nov 2026.
Performance Over six months the shares fell 5.4%, against +9.3% for the median peer and +3.8% for the India market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 8.1% over the last twelve months (peer median +2.3%); the operating margin is 28.2% (peer median 10.6%).
Valuation It trades at 37.1× forward earnings against a peer median of 21.5× (3rd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 129.9 points above its cost of capital (11.2% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹32.1B | ₹31.0B | ₹29.8B | ₹24.8B | ₹22.6B |
| Revenue growth | — | +4% | +20% | +10% | — |
| Gross profit | ₹16.7B | ₹15.1B | ₹13.5B | ₹9.06B | ₹8.68B |
| EBITDA | ₹9.80B | ₹9.69B | ₹8.23B | ₹5.42B | ₹4.88B |
| Net income | ₹6.84B | ₹6.54B | ₹5.57B | ₹3.56B | ₹2.89B |
| Free cash flow | n/a | ₹5.89B | ₹3.02B | ₹3.96B | ₹3.50B |
| Capital expenditure | n/a | ₹433M | ₹436M | ₹787M | ₹1.16B |
| Total debt | ₹200,000 | ₹200,000 | ₹500,000 | ₹500,000 | ₹1.20M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gillette India GILLETTE.NS | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% |
| Godrej Consumer Products GODREJCP.NS | $9.75B | -12% | +12% | 18% | 39.1× | 32.9% |
| Edgewell Personal Care EPC | $1.30B | +67% | -10% | 7% | 14.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GILLETTE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.2% | +4.9% | 9th lowest of 21 |
| 6-month return | -5.4% | +9.3% | 8th lowest of 21 |
| Distance from 52-week high | -20.0% | -22.4% | 10th highest of 21 |
| Revenue growth (TTM) | +8.1% | +2.3% | 6th highest of 21 |
| Operating margin | 28.2% | 10.6% | 2nd highest of 21 |
| Forward P/E | 37.1× | 21.5× | 3rd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 14.9% | -1.6% | 5th most demanding of 18 |
| Growth delivered (Del g) | +13.0% | +4.6% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | +1.8 pp | -4.0 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +129.9 pp | +5.1 pp | highest of 20 |
| EV / EBITDA | 23.5× | 10.3× | most expensive of 17 |
| Net debt / EBITDA | -0.6× | -0.8× | 8th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |